| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Scoping commenced. |
| Process | MTA Standard |
| ID number | 6195 |
Provisional Schedule
| Committee meeting | 04 December 2024 |
Project Team
| Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
| External Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
| Companies sponsors | Biogen (Nusinersen) |
| Roche (Risdiplam) | |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Gene People |
| Muscular Dystrophy UK | |
| Spinal Muscular Atrophy UK | |
| TreatSMA | |
| Professional groups | Adult SMA Reach |
| Association of British Neurologists | |
| British Paediatric Respiratory Society | |
| British Society of Physical and Rehabilitation Medicine | |
| Royal College of Physicians | |
| SMA Reach UK | |
| UK National Screening Committee | |
| Comparator companies | Novartis Gene Therapies, Inc. (onasemnogene abeparvovec) (confidentiality agreement signed, participating) |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Welsh Government | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 August 2024 | Assessment report sent for information |
| 05 January 2024 | Invitation to participate |
| 28 July 2023 - 25 August 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 July 2023 | In progress. Scoping commenced. |
For further information on our processes and methods, please see our CHTE processes and methods manual